
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc's enterprise value stands at approximately $430 million, suggesting significant growth potential, with estimates of 8-10 times upside to the current share price should its partnership with Novopro yield successful results. The management's confidence in leveraging prior experience with SEP-786 for improved efficiency in Phase 1 trials, combined with preclinical findings indicating a longer half-life for SEP-631, positions the company favorably for advancing its drug pipeline. Additionally, if SEP-631 can match the efficacy of Xolair, it could potentially reach blockbuster status, aligning with the company's focus on innovative treatments in endocrinology, immunology, and metabolic disease.
Bears say
Septerna Inc faces several fundamental risks that could negatively impact its stock performance, including potential delays in clinical development and setbacks in trials for its drug candidates, such as SEP-631. Additionally, the company's partnership with Novo Nordisk presents risks that could hinder progress and market approval for its therapies. Furthermore, concerns regarding lower-than-expected market penetration rates and long-term dilution risks add to an already challenging outlook, compounded by a recent transaction in the obesity sector that highlights a potential valuation gap.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares